Reviving research into psychedelic drugs

Author: Neidpath A.

Full text

I would like to endorse The Lancet‘s comments about the need to revive research into psychedelic drugs (April 15, p 1214).1

I am the director of the Beckley Foundation, a charitable trust that is starting a programme of research into the neurophysiological effects of lysergic acid diethylamide (LSD) and other compounds to discover whether, or how, they might be used as an adjunct to psychotherapy. Unfortunately, since I have been told that we would not get ethics approval in the UK, we have been forced to pursue the research elsewhere.

This is a great pity because we understand that, were ethics permission granted, several UK research groups are extremely able and willing to do this important work.

I declare that I have no conflict of interest.